Latest Breaking News On - James katz - Page 1 : comparemela.com
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasisFARMINGTON HILLS, Mich., Sept. 07, 2023 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that it will pre
United-statesAustriaViennaWienAmericansJames-katzBindu-manneCathleen-mccabeOcuphire-pharmaRick-rodgersCorey-davisSheraz-daya